Obio Technology (Shanghai) Corp., Ltd.

688238

CNE1000059N9

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 13/06/2024 BST			5-day change	1st Jan Change
5.17 ^CNY	-2.64%		+2.38%	-42.49%

05-30	OBiO Technology Officially Launches the Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases	CI
05-16	Obio Technology's Shareholders to Offload Up to 1.5% Stake	MT

Obio Technology Corp., Ltd.(SHSE:688238) added to Shanghai Stock Exchange Composite Index

March 22, 2023 at 04:00 am

Obio Technology (Shanghai) Corp., Ltd Added to Shanghai Stock Exchange Composite Index.

Latest news about Obio Technology (Shanghai) Corp., Ltd.

OBiO Technology Officially Launches the Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases	05-30	CI
Obio Technology's Shareholders to Offload Up to 1.5% Stake	05-16	MT
Obio Technology Corp., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-28	CI
Obio Technology Corp., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
Obio Technology Corp., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	25/10/23	CI
Obio Launches Gmp Production Facility Intelli-M to Expedite Innovative and Advanced Therapies to Patients Who Are in Need	27/09/23	CI
Obio Technology Corp., Ltd.(XSSC:688238) added to S&P Global BMI Index	18/09/23	CI
Obio Technology Corp., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23/08/23	CI
Obio Technology Corp., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/04/23	CI
Obio Technology Corp., Ltd.(SHSE:688238) added to Shanghai Stock Exchange Composite Index	22/03/23	CI
Obio Technology Corp., Ltd.(SHSE:688238) added to Shanghai Stock Exchange A Share Index	22/03/23	CI
Certain A Shares of Obio Technology Corp., Ltd. are subject to a Lock-Up Agreement Ending on 22-MAR-2023.	21/03/23	CI
Obio Technology Posts 24.6% Drop in 2022 Profit	27/02/23	MT
Obio Technology Corp., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23/02/23	CI
Obio Technology to Invest Another $3 Million on US Subsidiary	06/02/23	MT
OBiO Technology Corp., Ltd. Announces United States Food and Drug Administration Accepts Its GMP Plasmid DNA Drug Master File	16/01/23	CI
Obio Technology Eyes 129 Million Yuan Purchase of Public Rental Housing For Staff	08/12/22	MT
Obio Technology Corp., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	26/10/22	CI
Obio Technology Corp., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	24/08/22	CI
Obio Zhizao Gene Technology Co., Ltd announced that it has received CNY 600 million in funding from Obio Technology Corp., Ltd.	06/07/22	CI

Chart Obio Technology (Shanghai) Corp., Ltd.

Duration

Period

Chart Obio Technology (Shanghai) Corp., Ltd.

More charts

OBio Technology Shanghai Corp Ltd is a China-based company mainly engaged in the research and development and production of recombinant viruses for gene therapy. The Company is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The Company mainly conducts business in the European and American markets and the domestic market.

Sector

Pharmaceuticals

Calendar

21/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Obio Technology (Shanghai) Corp., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.17 CNY

Average target price

8.2 CNY

Spread / Average Target

+58.61%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
OBIO TECHNOLOGY (SHANGHAI) CORP., LTD.	-42.49%	461M
ELI LILLY AND COMPANY	+50.70%	791B
NOVO NORDISK A/S	+41.96%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.02%	246B
ROCHE HOLDING AG	+1.27%	225B
NOVARTIS AG	+11.95%	218B
AMGEN INC.	+3.68%	160B

Other Pharmaceuticals

Obio Technology (Shanghai) Corp., Ltd.

Equities

688238

CNE1000059N9

Pharmaceuticals

Obio Technology Corp., Ltd.(SHSE:688238) added to Shanghai Stock Exchange Composite Index

Latest news about Obio Technology (Shanghai) Corp., Ltd.

Chart Obio Technology (Shanghai) Corp., Ltd.

Company Profile

Income Statement Evolution

Ratings for Obio Technology (Shanghai) Corp., Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals